Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
about
Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase IIalphaCell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activitiesPurification and characterization of a DNA-binding heterodimer of 52 and 100 kDa from HeLa cellsActive heterodimers are formed from human DNA topoisomerase II alpha and II beta isoformsEffects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine groupRecovery of the poisoned topoisomerase II for DNA religation: coordinated motion of the cleavage core revealed with the microsecond atomistic simulation.Engineered picornavirus VPg-RNA substrates: analysis of a tyrosyl-RNA phosphodiesterase activity.Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossoversTopoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.Antifungal agents: chemotherapeutic targets and immunologic strategies.Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.DNA organization affects cellular radiosensitivity and detection of initial DNA strand breaks.Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging.Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cellsAberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.Autonomous parvovirus DNA replication requires topoisomerase I and its activity is increased during infection.Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.In vitro assays used to measure the activity of topoisomerases.Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.Biochemical characteristics and physiological significance of major DNA topoisomerases.Site-directed mutagenesis of conserved aspartates, glutamates and arginines in the active site region of Escherichia coli DNA topoisomerase I.Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiaePurification and characterization of human topoisomerase I mutants.Functional dissection of the C-terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani.Association between the p170 form of human topoisomerase II and progeny viral DNA in cells infected with herpes simplex virus type 1.Archaebacterial reverse gyrase cleavage-site specificity is similar to that of eubacterial DNA topoisomerases I.Influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumour cell lines differing in p53 status.Detection of DNA double-strand breaks through the cell cycle after exposure to X-rays, bleomycin, etoposide and 125IdUrd.Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH Dependency.Cloning and characterization of the 5'-flanking region for the human topoisomerase III gene.9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy.N-terminal region of the large subunit of Leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit.Topoisomerase IV catalysis and the mechanism of quinolone action.Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administration.Cell type-dependent regulation of human DNA topoisomerase III alpha gene expression by upstream stimulatory factor 2.Determination of 5' and 3' DNA triplex interference boundaries reveals the core DNA binding sequence for topoisomerase II.Dual topoisomerase I/II poisons as anticancer drugs.A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.Etoposide sensitivity and topoisomerase II activity in Chinese hamster V79 monolayers and small spheroids.
P2860
Q22010515-FAF1A8AF-877D-4DBD-ACAF-F34FF432A175Q24322851-CED5C181-30DB-4B4F-8C67-742C6523D50AQ24527699-34420EB0-A52F-4596-9B15-693191C278ECQ24629778-D92CAEF0-6E25-485F-87F8-7E0C0A370B04Q24671373-E0B447DB-C7C0-4DCF-812C-3259743CF8AAQ30661486-BD073C21-65B0-455C-84D3-332F9935EE18Q33847831-95B1ACF8-2880-4D54-8EE1-A4790EDFE2E6Q33923932-32956AA8-9D13-4101-81F4-FA7A7167BDE2Q34314426-67E3A107-5074-49F7-BD38-7899D557800DQ34400044-AC6492B0-8E1B-41C1-ADAF-9DE3B252E5DFQ34805496-58D1E9CA-E964-4E11-BABC-A41BC3F05238Q35266968-7DE2B189-7EB7-4797-BD98-F6526B78F7A4Q35976079-023C5D3C-7C67-4FBA-8925-8B2728F45CB9Q35978105-FD107034-8679-4954-94DA-178EF5583C92Q35982550-D02618F2-28BC-4EBF-AB22-078FD8303D12Q36616756-0B19FD7B-C561-4B80-9056-6E8DB8CA0C54Q36683177-D67EF97B-AC16-4B2C-A815-0D8F5AD1121FQ37585969-D7D4C5AF-F5D6-4C25-8EE4-DA87F8E4840BQ37876263-3C678087-3D6E-43A9-8B7A-E0B9075A09ACQ38273585-AE7F2596-03E7-47F8-99F9-70DB9B59BDA1Q38321795-632CEB72-32C0-4260-ACE1-65154F8B4C88Q38337782-66C07AB6-E0A3-4A0B-8803-E7976816F5B4Q38356131-DE3FFFDE-BA9E-4360-B141-7E118304E8CBQ38361294-AFEBCF60-098F-4D17-A407-9D77B5457DB5Q39922598-6E619F39-FD1D-43BB-9C34-7559F4956FB0Q40039006-3F52FF6F-AE53-4891-A48A-F2E7FAB5D2DCQ40516307-E686AF36-6A41-4C6E-9781-12068DD7457FQ41078305-C26CA45E-CFA0-415F-BDA5-B89FB0F87747Q41525219-5B1B74E3-D5D0-415F-8F36-8762C764C249Q41700142-96ED1958-99A3-40CD-BD49-FF6EE059781DQ42461527-ACF7A90F-9425-4114-92EA-52D6E93ED484Q43652311-8F1A1C7E-ECFC-4F44-96B3-1183D9440C0AQ45265133-27E3B9B5-5ECD-4CD7-987F-D32BB880C816Q47891380-A214603D-695E-4C48-8EB4-6C4B849B6062Q48179253-D29CB982-F2FF-4F98-BF36-F0CC49E3F76DQ52129568-0DD0DD2F-D7A5-4D15-B38E-80193A03BD16Q52346978-41D222FB-D472-4963-B309-C2488ACA1E36Q53668428-030F24CC-CDFD-4798-A171-9FAEAD4AD889Q54182306-EF2CD35C-633C-404F-B2FF-45160B6A8135Q54290061-E195C16D-4563-417C-8584-E719FA1BE773
P2860
Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
@en
type
label
Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
@en
prefLabel
Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
@en
P1476
Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
@en
P2093
Osheroff N
P304
P356
10.1016/0163-7258(89)90108-3
P577
1989-01-01T00:00:00Z